Mutual Funds
A Vanguard Fund Plays Defense With Health Stocks
From Kiplinger's Personal Finance magazine, March 2009
- Comments
- Email This Article
- Print This Article
- Order a Reprint
Advertisement
It may be cold comfort for beleaguered investors, but Vanguard Primecap Core's performance is in the top 3% of large-company growth funds over the past year, according to Morningstar. The fund's managers have placed a big bet on a classic defensive sector, with 28% of assets in health-care stocks, including the six top holdings (among them European drug giants Novartis, GlaxoSmithKline and Roche).
The managers say share prices don't reflect the promising drugs and devices now in development (Medtronic is another top-six holding). They also like the sturdy balance sheets of health-care companies and the potential for growth despite the recession.
Reach your goals. See portfolios using Kiplinger 25 funds.
Track performance. Get updated data for the Kiplinger 25 funds.
Permission to post your comment is assumed when you submit it. The name you provide will be used to identify your post, and NOT your e-mail address. We reserve the right to excerpt or edit any posted comments for clarity, appropriateness, civility, and relevance to the topic.
View our full privacy policy